ORINY Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 15:49):

Stats
Today's Volume	21.00
Average Volume	164.00
Market Cap	5.46B
EPS	$0 ( 2024-04-25 )
Next earnings date	( $0 ) 2024-07-15
Last Dividend	$0.870 ( 2023-03-23 )
Next Dividend	$0 ( N/A )
P/E	21.08
ATR14	$0 (0.00%)

Orion Oyj Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Orion Oyj Financials

Annual	2023
Revenue:	$1.19B
Gross Profit:	$640.60M (53.77 %)
EPS:	$1.550

FY	2023
Revenue:	$1.19B
Gross Profit:	$640.60M (53.77 %)
EPS:	$1.550

FY	2022
Revenue:	$1.34B
Gross Profit:	$849.00M (63.33 %)
EPS:	$2.49

FY	2021
Revenue:	$1.04B
Gross Profit:	$593.50M (57.01 %)
EPS:	$0.690

Financial Reports:

No articles found.

Orion Oyj Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0.870 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Orion Oyj Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 5.69 - Stable (13.85%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.739	2016-03-22
Last Dividend	$0.870	2023-03-23
Next Dividend	$0	N/A
Payout Date	2023-04-17
Next Payout Date	N/A
# dividends	9	--
Total Paid Out	$7.52	--
Avg. Dividend % Per Year	0.00%	--
Score	3.36	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	5.69
Div. Directional Score	9.24	--

Next Divdend (Est)
(2024-10-07)

$0 Estimate 0.00 %

Dividend Stability

0.06 Very Bad

Dividend Score

3.36

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for OTC

Symbol	Title	Last dividend	Frequency	Yearly Dividend
YAHOF	Ex Dividend Junior	2024-03-28	Annually	0.00%
LNVGY	Ex Dividend Knight	2023-07-26	Annually	0.00%
CDEVY	Ex Dividend Knight	2023-08-22	Semi-Annually	0.00%
SNPHF	Ex Dividend Knight	2023-09-28	Annually	0.00%
GASNY	Ex Dividend Knight	2023-08-03	Semi-Annually	0.00%
NCMGY	Ex Dividend Knight	2023-08-22	Annually	0.00%
CNLPM	Ex Dividend Knight	2023-07-07	Quarterly	0.00%
THNPY	Ex Dividend Knight	2023-05-18	Annually	0.00%
HMLN	Ex Dividend Junior	2023-06-13	Annually	0.00%
APLO	Ex Dividend Junior	2023-09-11	Quarterly	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.178	1.500	6.45	9.67	[0 - 0.5]
returnOnAssetsTTM	0.148	1.200	5.05	6.06	[0 - 0.3]
returnOnEquityTTM	0.270	1.500	8.11	10.00	[0.1 - 1]
payoutRatioTTM	0.191	-1.000	8.09	-8.09	[0 - 1]
currentRatioTTM	1.782	0.800	6.09	4.87	[1 - 3]
quickRatioTTM	1.002	0.800	8.81	7.05	[0.8 - 2.5]
cashRatioTTM	0.396	1.500	8.91	10.00	[0.2 - 2]
debtRatioTTM	0.133	-1.500	7.78	-10.00	[0 - 0.6]
interestCoverageTTM	62.84	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	1.603	2.00	9.47	10.00	[0 - 30]
freeCashFlowPerShareTTM	0.999	2.00	9.50	10.00	[0 - 20]
debtEquityRatioTTM	0.275	-1.500	8.90	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.551	1.000	4.15	4.15	[0.2 - 0.8]
operatingProfitMarginTTM	0.196	1.000	8.09	8.09	[0.1 - 0.6]
cashFlowToDebtRatioTTM	1.156	1.000	4.69	4.69	[0.2 - 2]
assetTurnoverTTM	0.835	0.800	7.76	6.21	[0.5 - 2]
Total Score				12.79

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	10.55	1.000	9.04	0	[1 - 100]
returnOnEquityTTM	0.270	2.50	8.78	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	0.999	2.00	9.67	10.00	[0 - 30]
dividendYielPercentageTTM	2.91	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	1.603	2.00	9.47	10.00	[0 - 30]
payoutRatioTTM	0.191	1.500	8.09	-8.09	[0 - 1]
pegRatioTTM	-8.39	1.500	-10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.184	1.000	7.89	0	[0.1 - 0.5]
Total Score				5.69

Orion Oyj

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and internationally. It provides prescription drugs and self-care products, including Nubeqa for the treatment of prostate cancer; dexdor and Precedex for intensive care sedative; Stalevo and Comtess/Comtan for Parkinson's disease; Simdax for acute decompensated heart failure; and Fareston for breast cancer, as well as Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. The company also offers veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; and APIs for generic and proprietary drugs, as well as provides contract manufacturing services. In addition, it markets and sells veterinary drugs manufactured by other international companies. The company serves various healthcare service providers and professionals, such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centers, clinics, and laboratories, as well as consumers with pets. Orion Oyj has partnership with Propeller Health to connect the Easyhaler(R) product portfolio for the treatment of asthma and COPD; and a research collaboration and license agreement with Alligator Bioscience AB (publ) to discover and develop new bispecific antibody cancer therapeutics. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.